Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Related: Analyst revises AbbVie stock price target on drug-sale estimates Sales eroded, however, as Humira faced competition ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

Botox Cosmetic expands beyond face for the first time as FDA approves the anti-wrinkle therapy for treating platysma bands.

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...